Please login to the form below

Not currently logged in
Email:
Password:

GSK signs biopharma deal with Lonza

GlaxoSmithKline will support the development of its biopharmaceutical pipeline in a new agreement with Lonza

Lonza has agreed to supply GlaxoSmithKline(GSK) with manufacturing capacity for five early stage monoclonal antibodies to support the development of GSK's biopharmaceutical pipeline.

The agreement will see Lonza – a major supplier to the pharmaceutical, healthcare and life science industries – manufacture clinical trial batches of five compounds currently in phase I and II development for GSK.

Flexible capacity will also be provided by Lonza allowing GSK to respond to future progress in the development of the antibodies.

Others details, including financial terms, were not disclosed.

Speaking about the agreement, Dr Stephan Kutzer, chief operating officer of Lonza Custom Manufacturing said: "We see this as a relationship that will bring significant benefits to both parties."

As well as providing manufacturing capacity for GSK, the deal will also see Lonza provide advice on GSK's plans to expand its own biopharmaceutical manufacturing capabilities. This includes the construction of a biopharmaceutical manufacturing facility within the UK.

"Our goal is to establish a portfolio of biopharmaceutical products that by 2015 consistently exceeds 20 per cent of our R&D pipeline," said Ian Tomlinson, head of biopharm research and development, GSK. "To make this a reality we need to ensure that we have the right resources in place, which include flexible and expert manufacturing capabilities, to enable us to ultimately create and deliver these future medicines to patients."

9th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....

Infographics